(Q38757411)

6 September 2017

title

Idelalisib for treatment of B-cell malignancies (English)

1 reference

6 September 2017

Bryan Do

1

1 reference

6 September 2017

Morgan Mace

series ordinal

2

1 reference

6 September 2017

Amber Rexwinkle

series ordinal

3

1 reference

6 September 2017

publication date

1 March 2016

1 reference

American Journal of Health-System Pharmacy

6 September 2017

published in

1 reference

6 September 2017

volume

73

1 reference

6 September 2017

issue

8

1 reference

6 September 2017

page(s)

547-555

1 reference

6 September 2017

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

31 March 2020

How I treat CLL up front

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

The optimal management of follicular lymphoma: an evolving field

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

How I treat indolent lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Management of adverse events associated with idelalisib treatment: expert panel opinion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

The average body surface area of adult cancer patients in the UK: a multicentre retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

The treatment of relapsed refractory chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150281

31 March 2020

Identifiers

DOI

10.2146/AJHP150281

1 reference

6 September 2017

1 reference